Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Army
Moodys
Medtronic
Chubb
UBS
Express Scripts
Deloitte
Cantor Fitzgerald

Generated: June 21, 2018

DrugPatentWatch Database Preview

Bayer Healthcare Company Profile

« Back to Dashboard

Summary for Bayer Healthcare
International Patents:163
US Patents:4
Tradenames:22
Ingredients:12
NDAs:28
Patent Litigation for Bayer Healthcare: See patent lawsuits for Bayer Healthcare

Drugs and US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc RID MOUSSE piperonyl butoxide; pyrethrins AEROSOL;TOPICAL 021043-001 Mar 7, 2000 DISCN No No ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc CLARITIN loratadine CAPSULE;ORAL 021952-001 Jun 16, 2008 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc MIRALAX polyethylene glycol 3350 FOR SOLUTION;ORAL 022015-001 Oct 6, 2006 OTC Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bayer Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 7,399,772 ➤ Sign Up
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 4,863,931*PED ➤ Sign Up
Bayer Healthcare Llc CLARITIN REDITABS loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-002 Nov 27, 2002 4,659,716*PED ➤ Sign Up
Bayer Healthcare Llc CLARITIN loratadine TABLET;ORAL 019658-002 Nov 27, 2002 4,659,716*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER HEALTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20

Non-Orange Book US Patents for Bayer Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,514,520 Stabilized antihistamine syrup ➤ Sign Up
8,129,386 Fused azole-pyrimidine derivatives ➤ Sign Up
6,939,550 Stabilized antihistamine syrup ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bayer Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB01/012 United Kingdom ➤ Sign Up PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Chinese Patent Office
Boehringer Ingelheim
Teva
Medtronic
McKinsey
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.